Positive result in APPA Phase I clinical trial

AKLRD has successfully completed a Phase I APPA in Osteoarthritis (OA) trial. The Principal Investigator of this study summarized in the results that the primary endpoint had been met as “APPA was demonstrated to be safe and well-tolerated by all subjects in the trial”. The full study report will be available shortly. The National Institute […]

Read More

Important new evidence on the mode of action of APPA

Previous work has shown that the anti-inflammatory effects seen with APPA results from upregulation of Nrf-2 and reduction of NF-kB activity (see news item Summary of Effects of APPA on Neutrophils). Harmonisation of the molecular cross-talk between these intracellular messengers is known to reduce the levels of COX-1 and COX-2, enzymes that are inhibited by […]

Read More

Former investment banker appointed CFO of AKL

AKL Research and Development (AKLRD), a company developing an investigational osteoarthritis (OA) medicine, has announced the appointment of Michael Martin as its Chief Financial Officer. With more than 40 years’ global corporate finance experience advising companies in Mergers & Acquisitions, Initial Public Offerings and private equity, Mr Martin brings a wealth of deal experience to […]

Read More

AKLRD and Nordic Bioscience announce collaboration

AKL Research and Development (AKLRD) and Nordic Bioscience Clinical Development, have announced a risk-share agreement to assess the efficacy of a novel, oral medicine, APPA, in a phase II trial of Osteoarthritis (OA). The collaboration was announced at the Osteoarthritis Research Society International (OARSI) World Congress 2019 in Toronto, Canada.  The partnership will assess the […]

Read More

An important milestone in the development of APPA

The Phase I clinical trial at Liverpool is designed to test the safety of APPA.  The first stage is now complete, and the clinical trial dose escalation committee has approved the transition from a single dose in healthy volunteers to multiple ascending 2 week dosing in osteoarthritis patients. In this part of a clinical trial, […]

Read More

Dr Annalisa Jenkins and Lord Michael Grade as Advisors

AKL Research and Development (AKLRD), a company developing an investigational osteoarthritis (OA) medicine, announces the appointment of Dr Annalisa Jenkins and Lord Michael Grade as advisors. Dr Jenkins is former Head of Global Research & Development and Executive Vice President Global Development & Medical at Merck Serono. Lord Grade is former Chairman of the BBC. […]

Read More